Clinical Trial Update: Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dabrafenib and trametinib in patients with Erdheim-Chester disease harboring BRAF V600E mutation has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erdheim-chester Disease

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: National Human Genome Research Institute (NHGRI) | Conditions: BRAF V600E Mutation | Phase 2 | Status: COMPLETED | Results posted: 2021-06-07